Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
  • A61K38/13—Cyclosporins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to the use of a cyclic undecapeptide for the preparation of an administrable drug in a situation of myocardial ischemia.
• Myocardial ischemia is defined as an imbalance between needs and oxygen supply. This imbalance leads to a disorder of cardiac function. Myocardial ischemia is, in the great majority of cases, caused by a deficiency of the blood flow to the cardiac muscle tissue, depriving or drastically reducing the myocardial cells in oxygen supply. Ischemia may be due to obstruction of a vessel (thrombosis) or reduction of the internal diameter of an artery (stenosis) or decreased coronary blood flow (hypoperfusion) such as in circulatory insufficiency states during severe sepsis with endotoxic shock. With respect to severe sepsis, it also causes hemodynamic dysfunction with direct myocardial depression.
• Reperfusion is defined as the reestablishment of an adequate blood circulation within an ischemic tissue allowing to reach again the balance between needs and oxygen supply.
• the reperfusion during a complete interruption of the coronary blood flow is carried out by disobstruction of the occluded artery.
• Infarctions are consecutive to ischemia.
• the term infarction defines a circumscribed focus of tissue necrosis.
• myocardial infarction causes the destruction of a part of the heart due to death of the heart muscle cells.
• Myocardial infarction is a very common disease. By way of example, in France, about 180,000 to 200,000 people per year are affected by this predominant disease in humans. It appears, in priority, in subjects with cardiovascular risk factors such as smoking, obesity, diabetes, hyperlipidemia or high blood pressure.
• Acute myocardial infarction is an absolute cardiological emergency that involves management by specialized medical and hospital services with acute phase therapy to reperfuse the heart muscle. ischemic and prevent and / or limit possible complications related to infarction frequently leading to the death of patients in the first hours or the first days.
• the extent of myocardial infarction is critical to the contractile functional recovery of the myocardium and the long-term prognosis of patients.
• reperfusion undoubtedly protects myocardial cells from cell death caused by the persistence of ischemia, it is also accompanied by deleterious effects on contractile function (myocardial stunning), heart rhythm (occurrence of arrhythmias), and tissue perfusion ("no-reflow"). Recent data even indicate that reperfusion can also paradoxically kill some of the reperfused cells (reperfusion necrosis).
• drugs belonging to different therapeutic classes such as, for example, those of platelet aggregation inhibitors such as acetylsalicylic acid, that of beta-blockers, that of the inhibitors of the myocardial infarction, conversion enzyme (IEC) or that of statins have a beneficial effect on the prognosis of patients.
• platelet aggregation inhibitors such as acetylsalicylic acid, that of beta-blockers, that of the inhibitors of the myocardial infarction, conversion enzyme (IEC) or that of statins
• IEC conversion enzyme
• pre-conditioning the repetition of ischemia-reperfusion episodes of short duration (not causing irreversible cellular damage by themselves) carried out either before (“pre-conditioning") or after (“post-conditioning") the period of ischemia responsive to infarction
• post-conditioning the period of ischemia responsive to infarction
• pre-conditioning therapies are not clinically applicable to AMI patients for physiopathological and practical reasons.
• post-conditioning treatments they only apply to a limited number of patients with acute myocardial infarction, such as those who can be treated with percutaneous transluminal coronary angioplasty.
• the administration proposed in many experimental models corresponds to a continuous perfusion of the heart before, during and after the period of ischemia, continuing during all or part of the reperfusion phase. This aspect of administration is not applicable as such in the clinic and the optimal mode of administration is not known.
• new adjuvant therapies that must be administered during reperfusion, which have the cardioprotective effect of limiting the size of the myocardial necrosis and improving its function, are necessary in the treatment of certain situations of myocardial ischemia-reperfusion, especially during acute myocardial infarction and / or depression and myocardial dysfunction due to severe sepsis.
• the window of time during which the drug is administered is important.
• the administration of the drug must begin imperatively before reperfusion, and possibly continue during it, in order to obtain the expected benefit in terms of limitation of the size of the myocardial infarction, contractile muscular recovery and of the patient's survival.
• the purpose of the present invention is to provide the clinician with medication to treat certain situations of myocardial ischemia, particularly during acute myocardial infarction and / or following severe sepsis, in adjuvant treatment with myocardial reperfusion, which has the effect of limiting the size of the infarct and improving its function.
• the present invention relates to the use of an undecapeptide cyclic having the structure of formula (I)
• MeBmt is the abbreviation N-methyl- (4R) -4-but-2E-en-1-yl-4-methyl- (L) threonine amino acid, ⁇ Abu that of L- ⁇ -aminobutyric acid, MeAIa that of N-methyl-L-alanine, EtVaI that of N-ethyl-L-valine, Val that of valine, MeLeu that of N-methyl-L-Leucine, AIa that of L-alanine, (D) AIa that of D-alanine and MeVaI that of N-methyl-L-valine.
• Cyclosporin A The numbering conventionally used to characterize the respective position of each of the amino acids constituting Cyclosporin A is also used to define the structure of the cyclic undecapeptide of formula (I). Still with reference to cyclosporin A, the cyclic undecapeptide of formula (I) can also be called [MeAla] 3 - [EtVal] 4 -CsA.
• the situations of myocardial ischemia result from the reduction or cessation of the myocardial blood circulation, resulting, inter alia, in a reduction or cessation the supply of oxygen to this organ requiring recovery of blood flow or cardiac reperfusion.
• These situations of ischemia can manifest themselves by cardiac dysfunctions detectable among others by echo and electrocardiography. This phenomenon leads to cardiac cellular lesions detectable among other measures by biological markers such as cardiac enzymes, medical imaging such as ultrasound, nuclear scintigraphy, or nuclear magnetic resonance.
• Acute, sub-acute or chronic myocardial ischemia may be caused by, or associated with, a variety of factors or diseases.
• factors or diseases are, for example, acute myocardial infarction, angina pectoris, unstable angina, atherosclerotic diseases with thromboembolism, vasospasms, aneurisms of small and medium-sized arteries. and large vessels, hypotension due to heart disease or systemic including serious infections such as severe sepsis with or without septic shock or allergic reactions, hypotension due to the effect of one or more drugs, drugs, poisons, toxic products.
• secondary hypoperfusions following one or other of the following diseases or situations: diabetes mellitus, hyperlipidemia, thromboangiitis obliterans or Buerger's disease, Takayasu syndrome, cardiovascular syphilis, disorder of connective tissues such as Raynaud's disease, phlegmatia caerulea dolens or Gregoire's blue phlebitis, trauma to blood vessels including iatrogenic trauma such as surgery or organ transplants, operations of the heart and large vessels with or without the use of extracorporeal circulation techniques.
• diseases or situations diabetes mellitus, hyperlipidemia, thromboangiitis obliterans or Buerger's disease, Takayasu syndrome, cardiovascular syphilis, disorder of connective tissues such as Raynaud's disease, phlegmatia caerulea dolens or Gregoire's blue phlebitis, trauma to blood vessels including iatrogenic trauma such as surgery or organ transplants, operations
• acts also include, by way of example, the surgical insertion of implants, devices, grafts, prostheses or any other biomedical device or product, in particular cardiological devices.
• a non-limiting list of organs or tissues in which these ischemic situations may occur includes the heart, brain, kidneys, extremities, spleen, liver, stomach and gastrointestinal system including the small intestine, the colon and rectum, lungs and respiratory tracts, eyes, skin, muscles, pancreas, prostate, bone marrow, endocrine glands.
• cyclic undecapeptide of formula (I) is particularly suitable for the treatment of situations of myocardial ischemia, for the treatment of myocardial hypoperfusion-reperfusion, in particular during the occurrence of an acute myocardial infarction and / or cardiac dysfunction during severe sepsis.
• the treatment of situations related to ischemic myocardial is to administer to the subject said cyclic undecapeptide previously and / or during the recovery of blood flow or to an infusion in adequacy with the needs of oxygen in the heart or heart tissue.
• the blood circulation is restored by reperfusion obtained mechanically by coronary angioplasty and / or medically following a fibrinolysis treatment and / or following measures of drug resuscitation.
• the cyclic undecapeptide of formula (I) is preferably administered prior to said reperfusion.
• the start of the administration is spread out over a period preferably of the thirtieth minute preceding the reperfusion, more preferably during the 10 minutes preceding this reperfusion, preferably again during the periods preceding the reperfusion. 5 minutes before this reperfusion, preferably again during the minute preceding this reperfusion, until the reopening of the artery and / or since the restoration of blood flow.
• the beginning of the administration of said cyclic undecapeptide of formula (I) occurs in a period ranging from preferably, at the earliest at the time of the declaration of this sepsis and, preferably, at the latest 72 hours.
• the pharmaceutical preparation comprising the derivative is administered intravenously, intraarterially, intracoronally, or intra-myocardially preferably in bolus and / or followed by continuous infusion for ten hours after the onset of reperfusion.
• the administration of the pharmaceutical preparation by continuous infusion can then be done intravenously, or intra-arterially.
• the administration of the cyclic undecapeptide of formula (I) can be done separately and / or previously or concomitantly with this drug delivery and can be continued during this drug administration then during the ten hours following the restoration of the blood flow.
• the pharmaceutical preparation comprising the cyclic undecapeptide of formula (I) can then be administered as a single dose intravenously, preferably in bolus, and then it can be continued in continuous infusion for ten hours after the start of reperfusion. .
• the pharmaceutical composition comprising the cyclic undecapeptide of formula (I) as the active compound is in the form of a solution, a dispersion, or in the form of injectable depot formulations. These formulations may comprise the active compound in the form of nano-crystals, micelles, lipid emulsions, microemulsions or nanoparticulate suspensions.
• the pharmaceutical compositions for injectable solutions comprise said undecapeptide in combination with at least one pharmaceutically acceptable carrier. Prior to administration, the concentrated compositions are combined with suitable diluents, comprising at least one excipient, such as an isotonic agent, buffer or other pH-controlling agent, and a preservative.
• excipients can be added for the maintenance of the composition, a pH range of about 5.5 to about 8.5 and osmolarity of about 280 to about 400 mosm / L.
• the formulations usually used for The preparation of a Cyclosporin A drug is also suitable for carrying out the present invention.
• cyclic undecapeptide of formula (I) can also be done in addition to a standard anti-anginal treatment (beta-blocker, delayed nitro derivative, calcium antagonist, antiplatelet) and / or treatment of septic shock.
• a standard anti-anginal treatment beta-blocker, delayed nitro derivative, calcium antagonist, antiplatelet
• the administration of the undecapeptide is then either concomitant or sequential with at least a second active compound in said treatments.
• the cyclic undecapeptide of formula (I) is administered at a dose ranging from 0.1 mg / kg to 30 mg / kg, preferably from 0.1 mg / kg. kg to 20 mg / kg.
• the specialist knows how to establish the modality of administration, as regards the chronology, the mode of administration or the dose, so that an effective concentration of the cyclic undecapeptide reaches the hypoperfused cardiac tissue from the first seconds of reperfusion.
• FIG. 1 represents the survival curves of an ischemia-reperfusion model in mice and the influence of the cyclic undecapeptide of formula (I) on the post-infarction period.
• the black curve represents the survival rate over time of the mice treated with the pharmaceutical vehicle alone after reperfusion and the clear curve of the mice treated with the undecapeptide of the invention;
• FIG. 2 represents the survival curves of a model of septic shock in mice and the influence of the cyclic undecapeptic of formula (I) on the post-septic period.
• the curve with the triangles represents the survival rate over time of the mice treated with physiological saline only after induction septic shock and the curve with the squares, the mice treated with the undecapeptide of the invention.
• cyclic undecapeptide of formula (I) 35 mg / ml cremophor EL 650 mg / ml, ethanol 261 mg / ml
• the aim of this study is to test the cardioprotective effect of the cyclic undecapeptide of formula (I), otherwise called [MeAla] 3 - [EtVal] 4 -CsA, in terms of reduced size of measured myocardial infarction. hours after the onset of infarction.
• a thoracotomy is performed in the fourth left intercostal space.
• a marginal branch of the left circumflex coronary artery is ligated using a 3.0 suture silk thread.
• temperature, heart rate and blood pressure are controlled.
• the ligation is lifted (reperfusion) and the animals are kept for 4 hours in a controlled atmosphere, before euthanasia.
• a group of animals receives the pharmaceutical vehicle of
• Table 1 Myocardial infarction size as determined by the ratio of necrotic areas (NA) to risk area areas (AR) as a percentage. SD represents the standard deviation.
• Example 2 Model of ischemia-reperfusion in mice - Influence of rMeAlal3-rEtVall4-CsA on the post-infarction period (ventricular remodeling and survival)
• mice After anesthesia, the mice are intubated and ventilated by a rodent ventilator. The rectal temperature is monitored and maintained at 38 ° -39 ° C. After stemotomy, the anterior interventricular artery is ligated by an 8-0 polypropylene thread. Ischemia is visualized by the appearance of ST segment elevation on ECG (electrocardiogram) and myocardial pallor. After 25 minutes of occlusion, the ligature is lifted and the reperfusion controlled by visual inspection and disappearance of the ST segment elevation. The chest wall is closed by suture and the mice held in a temperature controlled atmosphere.
• ECG electrocardiogram
• a group of animals receives the vehicle of [MeAla] 3- [EtVal] 4-CsA; another group is treated with [MeAla] 3- [EtVal] 4-CsA intravenously (single injection at 10 mg / kg), 3 minutes before the ligation is lifted. The animals are followed for 30 days and the reported mortality for each group.
• the area at risk and the size of the infarct are determined.
• a blue dye is injected via the vena cava to determine the area at risk.
• the animals are anesthetized and the heart excised.
• the ventricle is cut into 5 thin slices and photographed. Incubation of these slices in 2,3,5-triphenyltetrazolium for 15 minutes at 37 ° C. makes it possible to differentiate between the living myocardial zones (brick red) and the necrotic ones Qaune pale).
• the slices are photographed.
• the areas of risk areas and infarcted myocardium are determined by planimetry.
• the size of the infarct and the area at risk are calculated and expressed as a percentage of the weight of the left ventricle.
• Table 2 Myocardial infarction size determined by ratio of necrotic areas (NA) to areas of risk areas (RA) in percentage 24 hours after reperfusion. SD represents the standard deviation.
• Table 3 Remodeling of the left ventricle studied by Doppler echocardiography: ejection fraction of the left ventricle 4 weeks after reperfusion. SD represents the standard deviation.
• Example 3 Septic shock model in mice - Influence of rMeAlal3-rEtVall4-CsA on the survival of septicemic mice with mvocardial dysfunction.
• mice peritonitis by ligation and cecal puncture is induced as follows: realization of a median laparotomy, externalization of the cecum and single puncture of it below the ileocaecal valve with a 21-gauge needle. The cecum is replaced in the abdominal cavity which is then sutured in 2 planes.
• mice receive by parenteral injection of analgesic nalbuphine.
• One group of animals receives physiological saline (control group); another group is treated with [MeAla] 3- [EtVal] 4-CsA at 10 mg / kg parenteral injection just after surgical induction of septic shock. The animals are followed for 4 days and the reported mortality for each group.
• Fig. 2 represents the improvement of survival of septic mice treated with [MeAla] 3 - [EtVal] 4 -CsA compared to the animals of the control group. 72 hours after induction of sepsis and start of treatment, the survival rate for the treated animals is about 60% compared to the animals in the control group whose 100% mortality is reached in 36 hours. This effect is mainly explained by the cardioprotective effect of [MeAla] 3- [EtVal] 4-CsA on myocardial dysfunction.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Epidemiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34933239

Family Applications (1)

Country Status (9)

Cited By (3)

Families Citing this family (2)

Citations (2)

Family Cites Families (2)

• 2006
  • 2006-01-10 ES ES06704161T patent/ES2387682T3/es active Active
  • 2006-01-10 PL PL06704161T patent/PL1853296T3/pl unknown
  • 2006-01-10 EP EP06704161A patent/EP1853296B1/fr active Active
  • 2006-01-10 SI SI200631402T patent/SI1853296T1/sl unknown
  • 2006-01-10 US US11/794,245 patent/US8889629B2/en not_active Expired - Fee Related
  • 2006-01-10 JP JP2007549909A patent/JP2008526816A/ja active Pending
  • 2006-01-10 DK DK06704161.6T patent/DK1853296T5/da active
  • 2006-01-10 WO PCT/EP2006/050140 patent/WO2006072639A1/fr not_active Ceased
  • 2006-01-10 PT PT06704161T patent/PT1853296E/pt unknown

Patent Citations (2)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events